Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation
暂无分享,去创建一个
G. Canonica | O. Pfaar | E. Heffler | D. Barber | U. Sahiner | G. Paoletti | M. Escribese | M. Giovannini | Montserrat Alvaro Lozano
[1] T. Laidlaw,et al. Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches , 2022, Frontiers in Immunology.
[2] C. Cordobés,et al. The Lights And The Shadows Of Controlled Sting Challenge With Hymenoptera. , 2022, Journal of investigational allergology & clinical immunology.
[3] G. Canonica,et al. Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ? , 2022, Frontiers in Allergy.
[4] O. Pfaar,et al. Update on the use of allergen challenge chambers in immunotherapy: clinical implications , 2022, Current opinion in allergy and clinical immunology.
[5] K. Nadeau,et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study , 2022, The Lancet.
[6] J. Bousquet,et al. One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence , 2021, Allergy.
[7] Xiqing Bian,et al. Metabolomics reveals a correlation between hydroxyeicosatetraenoic acids and allergic asthma: Evidence from three years' immunotherapy , 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[8] T. Zuberbier,et al. Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report , 2021, Allergy.
[9] A. Togias,et al. Differential Induction of Allergen-specific IgA Responses following Timothy Grass Subcutaneous and Sublingual Immunotherapy. , 2021, The Journal of allergy and clinical immunology.
[10] Feng Q. He,et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. , 2021, Immunity.
[11] R. Rabin,et al. Oral Immunotherapy for Food Allergy—a US Regulatory Perspective , 2020, Current Allergy and Asthma Reports.
[12] S. Durham,et al. EAACI Allergen Immunotherapy User's Guide , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[13] D. Wang,et al. Clinical Efficacy Evaluation of 1-Year Subcutaneous Immunotherapy for Artemisia sieversiana Pollen Allergic Rhinitis by Serum Metabolomics , 2020, Frontiers in Pharmacology.
[14] C. Akdis,et al. Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New? , 2020, Immunology and allergy clinics of North America.
[15] J. Martínez‐Botas,et al. Clinical utility of microarray B‐cell epitope mapping in food allergies: A systematic review , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[16] K. Nadeau,et al. Sustained Successful Peanut Oral Immunotherapy Associated with Low Basophil Activation and Peanut-Specific IgE. , 2019, The Journal of allergy and clinical immunology.
[17] B. Ruiter,et al. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. , 2019, The Journal of allergy and clinical immunology.
[18] S. Durham,et al. Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings? , 2019, Front. Immunol..
[19] M. Jenmalm,et al. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[20] Quefeng Li,et al. High‐ and low‐dose oral immunotherapy similarly suppress pro‐allergic cytokines and basophil activation in young children , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[21] M. Akdiş,et al. Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[22] Sheikh,et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy , 2018, Allergy.
[23] K. Nadeau,et al. The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses , 2018, Clinical Reviews in Allergy & Immunology.
[24] P. Demoly,et al. Perspectives in allergen immunotherapy: 2017 and beyond , 2018, Allergy.
[25] S. Durham,et al. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. , 2017, The Journal of allergy and clinical immunology.
[26] P Demoly,et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.
[27] A. Sheikh,et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis , 2017, Allergy.
[28] A. Henning,et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults , 2017, The Journal of allergy and clinical immunology.
[29] A. Togias,et al. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial , 2017, JAMA.
[30] W. van de Veen. The role of regulatory B cells in allergen immunotherapy. , 2017, Current opinion in allergy and clinical immunology.
[31] H. Huhtala,et al. Changes in biomarkers during a six‐month oral immunotherapy intervention for cow's milk allergy , 2016, Acta paediatrica.
[32] A. Henning,et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. , 2016, The Journal of allergy and clinical immunology.
[33] M. Pallardy,et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. , 2016, The Journal of allergy and clinical immunology.
[34] R. Van Ree,et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.
[35] K. Roskin,et al. Single B-cell deconvolution of peanut-specific antibody responses in allergic patients. , 2016, The Journal of allergy and clinical immunology.
[36] C. Rondón,et al. Initial immunological changes as predictors for house dust mite immunotherapy response , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[37] R. Valenta,et al. Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy , 2015, The Journal of allergy and clinical immunology.
[38] Mingqiang He,et al. Cytokine Responses to Specific Immunotherapy in House Dust Mite-Induced Allergic Rhinitis Patients , 2015, Inflammation.
[39] D. Gómez-Coronado,et al. Identification of novel peptide biomarkers to predict safety and efficacy of cow's milk oral immunotherapy by peptide microarray , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[40] J Christopher Love,et al. Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. , 2015, The Journal of allergy and clinical immunology.
[41] J. Schroeder,et al. Suppression of the immunologic response to peanut during immunotherapy is often transient. , 2015, The Journal of allergy and clinical immunology.
[42] A. Togias,et al. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge , 2015, Allergy.
[43] S. Durham,et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. , 2015, The Journal of allergy and clinical immunology.
[44] S. Vieths,et al. Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs. , 2015, The Journal of allergy and clinical immunology.
[45] A. Ikinciogullari,et al. Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response? , 2014, International Archives of Allergy and Immunology.
[46] Mengrong Li,et al. Predictive Factors for Clinical Response to Allergy Immunotherapy in Children with Asthma and Rhinitis , 2014, International Archives of Allergy and Immunology.
[47] M. Mäkelä,et al. Use of IgE and IgG4 epitope binding to predict the outcome of oral immunotherapy in cow's milk allergy , 2014, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[48] V. Backer,et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[49] S. Durham,et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. , 2014, The Journal of allergy and clinical immunology.
[50] M. Calderón,et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. , 2014, Journal of investigational allergology & clinical immunology.
[51] S. Durham,et al. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. , 2013, The Journal of allergy and clinical immunology.
[52] S. Zipfel,et al. Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom. , 2013, The Journal of allergy and clinical immunology.
[53] Franco H Falcone,et al. Basophilic histamine content and release during venom immunotherapy: Insights by flow cytometry , 2013, Cytometry. Part B, Clinical cytometry.
[54] T. Casale,et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. , 2013, The Journal of allergy and clinical immunology.
[55] A. Burks,et al. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. , 2013, The Journal of allergy and clinical immunology.
[56] Marco A Garcia,et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. , 2012, The Journal of allergy and clinical immunology.
[57] J. Schroeder,et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. , 2012, The Journal of allergy and clinical immunology.
[58] S. Durham,et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy , 2012, Allergy.
[59] D. Ebo,et al. Analyzing histamine release by flow cytometry (HistaFlow): a novel instrument to study the degranulation patterns of basophils. , 2012, Journal of immunological methods.
[60] S. Durham,et al. Rhinitis , sinusitis , and upper airway disease SQ-standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial , 2012 .
[61] F. Horak,et al. Changes in basophil activation during grass‐pollen sublingual immunotherapy do not correlate with clinical efficacy , 2011, Allergy.
[62] K. Reich,et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. , 2011, Clinical therapeutics.
[63] Y. Okamoto,et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. , 2011, Clinical immunology.
[64] A. Kemper,et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. , 2011, The Journal of allergy and clinical immunology.
[65] A. Burks,et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. , 2011, The Journal of allergy and clinical immunology.
[66] S. Durham,et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. , 2011, The Journal of allergy and clinical immunology.
[67] M. Blaiss,et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. , 2011, The Journal of allergy and clinical immunology.
[68] S. Spector,et al. Allergen immunotherapy: a practice parameter third update. , 2007, The Journal of allergy and clinical immunology.
[69] D. Bernstein,et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. , 2011, The Journal of allergy and clinical immunology.
[70] T. Arinami,et al. Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis. , 2010, The Journal of allergy and clinical immunology.
[71] A. Eifan,et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[72] H. Küchenhoff,et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long‐term immunotherapy for Hymenoptera venom allergy , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[73] J. Ceuppens,et al. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[74] N. Martinelli,et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. , 2009, The Journal of allergy and clinical immunology.
[75] G. Marseglia,et al. Adipokines and sublingual immunotherapy: preliminary report. , 2009, Human immunology.
[76] H. Ipsen,et al. A double‐blind placebo‐controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[77] B. Samoliński,et al. A follow‐up study of immunotherapy‐treated birch‐allergic patients: effect on the expression of chemokines in the nasal mucosa , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[78] M. Sormani,et al. Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-gamma production after sublingual immunotherapy in patients with allergic rhinitis. , 2008, Human immunology.
[79] S. Durham,et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. , 2008, The Journal of allergy and clinical immunology.
[80] H. Malling,et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.
[81] B. Bohle,et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. , 2007, The Journal of allergy and clinical immunology.
[82] S. Durham,et al. Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-β Expression1 , 2007, The Journal of Immunology.
[83] S. Durham,et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. , 2006, Journal of immunological methods.
[84] L. Håkansson,et al. Basophil Interleukin 4 and Interleukin 13 Production Is Suppressed during the Early Phase of Rush Immunotherapy , 2006, International Archives of Allergy and Immunology.
[85] O. Kalayci,et al. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis , 2006, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[86] William H. Yang,et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.
[87] L. Cosmi,et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down‐regulates allergen‐specific immunoglobulin E and increases both interferon‐γ‐ and interleukin‐10‐production , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[88] Franz König,et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. , 2005, The Journal of allergy and clinical immunology.
[89] A. Nordheim,et al. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation , 2005, Cell Research.
[90] C. Akdis,et al. Impact of Sublingual Immunotherapy on Specific Antibody Levels in Asthmatic Children Allergic to House Dust Mites , 2005, International Archives of Allergy and Immunology.
[91] B. Niggemann,et al. Lack of Detectable Alterations in Immune Responses during Sublingual Immunotherapy in Children with Seasonal Allergic Rhinoconjunctivitis to Grass Pollen , 2005, International Archives of Allergy and Immunology.
[92] A. Linneberg,et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. , 2004, Clinical biochemistry.
[93] P. Valent,et al. The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis , 2004, International Archives of Allergy and Immunology.
[94] S. Durham,et al. Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity1 , 2004, The Journal of Immunology.
[95] S. Durham,et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.
[96] S. Durham,et al. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.
[97] Marek Jutel,et al. IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy , 2003, European journal of immunology.
[98] T. Haahtela,et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System™ , 2002, Allergy.
[99] S. Durham,et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1 : Th2 cytokine ratios , 2002, Immunology.
[100] A. Kay,et al. Interleukin‐10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy , 2001, European journal of immunology.
[101] J. Oliver,et al. Negative regulation of FcϵRI signaling by FcγRII costimulation in human blood basophils , 2000 .
[102] C. Fanta,et al. Systemic Immunological Changes Induced by Administration of Grass Pollen Allergens via the Oral Mucosa during Sublingual Immunotherapy , 1999, International Archives of Allergy and Immunology.
[103] R. V. van Neerven,et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. , 1999, Journal of immunology.
[104] S. Durham,et al. Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.
[105] G. Canonica,et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. , 1999, The Journal of allergy and clinical immunology.
[106] Schlaak,et al. Monitoring allergen immunotherapy of pollen‐allergic patients: the ratio of allergen‐specific IgG4 to IgG1 correlates with clinical outcome , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[107] C. Akdis,et al. Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.
[108] J. Burgers,et al. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. , 1997, The Journal of allergy and clinical immunology.
[109] D. Golden,et al. Discontinuing venom immunotherapy: outcome after five years. , 1996, The Journal of allergy and clinical immunology.
[110] S. Voltolini,et al. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. , 1995, Journal of investigational allergology & clinical immunology.
[111] H. Jansen,et al. Monitoring human basophil activation via CD63 monoclonal antibody 435. , 1991, The Journal of allergy and clinical immunology.
[112] D. Richards,et al. Sub‐class of IgG anti‐bee venom antibody produced during bee venom immunotherapy and its relationship to long‐term protection from bee stings and following termination of venom immunotherapy , 1986, Clinical allergy.
[113] L. Lichtenstein,et al. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. , 1976, The Journal of clinical investigation.